Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Kanji Yamaguchi(Kyoto Prefectural University of Medicine), Anna Mae Diehl(Duke Medical Center), Shannon J. McCall(Duke Medical Center), Brett P. Monia(Ionis Pharmaceuticals (United States)), Xing Yu(Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine), Sanjay Bhanot(Ionis Pharmaceuticals (United States)), Sanjay Pandey(Ionis Pharmaceuticals (United States)), Jiawen Huang(Duke Medical Center), Liu Yang(Mayo Clinic), Yin-xiong Li(Duke Medical Center)
Cited by 1,001
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k